Observational studyThoracic cancer2025

Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients.

Min Jee Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.